CERE News and Press, Ceres Inc. From 03/01/22

Cerevel Therapeutics Holdings, Inc. (CERE) Q4 2021 Earnings Conference Call March 1, 2022 8:00 AM ET Company Participants Matthew Calistri - Vice President of Investor Relations Tony Coles - Chairperson & Chief Executive Officer Ray Sanchez - Chief Medical Officer John Renger - Chief Scie...

Cerevel Therapeutics press release (NASDAQ:CERE): Q4 GAAP EPS of -$0.40. Cash, cash equivalents and marketable securities as of December 31, 2021, were $618.0 million, compared to $383.6 million as of December 31, 2020. Financial Outlook: The Company anticipates R&D expenses for 2022...

Announced positive results from Phase 1 healthy volunteer trial of darigabat in acute anxiety On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Multiple late-stage clinical readouts expected in the next 1...

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, ...

Neurocrine exited 2021 with high single-digit qoq growth in Ingrezza prescriptions, but management is investing even more SG&A resources into recharging sales growth and momentum. Neurocrine has a large pipeline in terms of compounds and addressable indications, but the vast major...

Gainers: Brookdale Senior Living BKD +16%. American Shared Hospital Services AMS +12%. ImmunityBio IBRX +12%. I-Mab (NASDAQ:IMAB) +11%. Corvus Pharmaceuticals (NASDAQ:CRVS) +9%. Losers: Larimar Therapeutics LRMR -65%. Omnicell (NASDAQ:OMCL) -18%. M...

Cerevel Therapeutics (NASDAQ:CERE) reported results from a phase 1 trial of darigabat in healthy volunteers for acute anxiety. The company said the 7.5 mg twice-daily and the 25 mg twice-daily doses of darigabat showed clinically meaningful and statistically significant anxiolytic activi...

In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after eight days of dosing compared with placebo Darigabat was generally well-tolerated...

Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia Company expects to initiate Phase 2 program for emraclidine in schizophrenia by the middle of 2022, with data expected in the f...

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that Chairperson and Chief Executive Officer Tony Coles, M.D., will present at the...